Table 2 Patient and tumor characteristics of the the eligible studies
First author | Participations(n) | median age(Y) | Clinical stage | Histologic grade | Histology | Local treatment | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | HER2-low | HER2-zero | HER2-low/ HER2-zero | HER2-low | HER2-zero | HER2-low | HER2-zero | HER2-low | HER2-zero | HER2-low | HER2-zero |
| Â | HR+/HR- | HR+/HR- | Â | I/II/III | I/II/III | 1/2/3 | 1/2/3 | IDC/ILC/Other | IDC/ILC/Other | M/B | M/B |
Denkert | 703/395 | 445/767 | 49/48 | NR | NR | 24/417/657 | 15/322/875 | 927/45/126 | 1032/27/153 | NR | NR |
de Moura | 236/49 | 306/264 | 45.66/45.07 | 1/110/176 | 12/233/325 | 26/148/100 | 24/255/268 | 246/18/21 | 472/49/49 | 219/66 | 401/169 |
Domergue | 0/285 | 0/570 | 52.0/51.0 | NR | NR | NR | NR | 112/3/6 | 304/4/8 | 50/76 | 107/216 |
Alves | 29/12 | 11/20 | 53/50 | 0/14/27 | 0/19/12 | 9/19/13 | 1/17/13 | 31/6/4 | 26/3/2 | 32/9 | 20/11 |
Cosimo | 272/63 | 47/62 | 49/51.2 | NR | NR | 14/145/140 | 1/28/61 | NR | NR | 229/106 | 60/49 |
Shao | 171/55 | 56/32 | 47/47 | 0/108/118 | 0/38/50 | NR | NR | NR | NR | 182/32 | 74/10 |
Kang | 611/143 | 458/360 | 46/46 | NR | NR | 9/586/155 | 11/553/251 | 707/23/24 | 757/25/36 | NR | NR |
Zhou | 147/87 | 37/54 | 47/46 | 2/88/140 | 1/37/49 | 19/105/55 | 1/29/31 | 6/206/22 | 4/81/6 | NR | NR |
Qiao | 53/17 | 23/39 | NR | 0/57/13 | 0/51/11 | NR | NR | NR | NR | 61/9 | 58/4 |
Li | 426/252 | 138/211 | NR | 29/507/142 | 21/258/70 | NR | NR | 608/48/22 | 298/40/11 | 579/77 | 300/32 |
Pöschke | 661/267 | 235/208 | NR | NR | NR | 32/351/544 | 20/156/260 | 666/78/185 | 302/46/92 | 331/599 | 161/282 |
Li JJ | 188/51 | 19/25 | NR | 0/96/143 | 0/17/27 | NR | NR | NR | NR | 231/8 | 41/3 |
Zhong | 17,693/8993 | 6978/7836 | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Zhang | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |